SCHEMBL6101487

SCHEMBL6101487

CCCc1c(C(=O)O)nc2ccccn12

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.59
PTGS2 P35354 3/20 0.59
ALDH1A1 P00352 2/20 0.50
GAA P10253 1/20 0.50
AGTR1 P30556 1/20 0.48
AGTR2 P50052 1/20 0.48
KDM4E B2RXH2 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2505190 0.88 PTGS1 (0.62) PTGS1PTGS2ALDH1A1GAAKDM4E
SCHEMBL31040067 0.87 ALDH1A1 (0.52) PTGS1PTGS2ALDH1A1GAAKDM4E
SCHEMBL2219429 0.85 PTGS1 (0.59) PTGS1PTGS2ALDH1A1GAAAGTR1
SCHEMBL16464824 0.81 PTGS1 (0.57) PTGS1PTGS2ALDH1A1GAAKDM4E
SCHEMBL118693 0.78 PTGS1 (0.57) PTGS1PTGS2ALDH1A1GAAKDM4E
SCHEMBL15670597 0.78 KDM4E (0.53) PTGS1PTGS2ALDH1A1GAAAGTR1
SCHEMBL8352177 0.78 ALDH1A1 (0.68) PTGS1PTGS2ALDH1A1GAAKDM4E
SCHEMBL6100874 0.77 KDM4E (0.54) ALDH1A1GAAAGTR1AGTR2KDM4E
SCHEMBL7942161 0.77 KMT2A (0.49) PTGS1PTGS2ALDH1A1GAAKDM4E
SCHEMBL18131814 0.77 PTGS1 (0.56) PTGS1PTGS2ALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014746-A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands NEUROGEN CORPORATION 2006-01-19 US disclosed
US-6936617-B2 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands NEUROGEN CORPORATION (US) 2005-08-30 US disclosed
EP-1406906-A1 HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2004-04-14 EP disclosed
US-20030207885-A1 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands NEUROGEN CORPORATION 2003-11-06 US disclosed
WO-2003006471-A1 HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2003-01-23 WO disclosed
WO-2003006471-A1 HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014746-A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands GABRA5, GABRA2, GABBR1 PTGS1 2603/4885PTGS2 1302/4885ALDH1A1 797/4885
US-20030207885-A1 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands GABRA5, GABRA2, GABBR1 PTGS1 2192/4885PTGS2 1280/4885ALDH1A1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.